Association between the number of eggs and live birth
in IVF treatment: an analysis of 400 135 treatment cycles

#	Paper	IF	Citations
672	Grape seed extract inhibits in vitro and in vivo growth of human colorectal carcinoma cells. **2006**, 12, 6194-202		137
671	Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles. **2011**, 96, 585-9		10
670	Early menopause in mothers of children with Down syndrome?. **2011**, 96, 985-90		20
669	A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel?. **2011**, 96, 1058-61.e7		152
668	Prognostic testing for ovarian reserve. **2012**, 41-50		
667	Drugs used for ovarian stimulation: Clomiphene citrate, aromatase inhibitors, metformin, gonadotropins, gonadotropin-releasing hormone analogs, and recombinant gonadotropins. **2012**, 51-74		
666	The role of FSH and LH in ovulation induction: Current concepts. **2012**, 75-98		1
665	The use of AMH to tailor ovarian stimulation for IVF. **2012**, 131-139		
664	Clinical management of in vitro fertilization with preimplantation genetic diagnosis. **2012**, 30, 309-22		19
663	Reproductive potential of a metaphase II oocyte retrieved after ovarian stimulation: an analysis of 23 354 ICSI cycles. *Human Reproduction*, **2012**, 27, 2030-5	5.7	50
662	Anti-Mllerian hormone: clairvoyance or crystal clear?. *Human Reproduction*, **2012**, 27, 631-6	5.7	76
661	Ovarian stimulation protocols in assisted reproductive technology: an update. **2012**, 7, 319-330		4
660	Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. **2012**, 98, 657-63		67
659	Array CGH analysis shows that aneuploidy is not related to the number of embryos generated. *Reproductive BioMedicine Online*, **2012**, 24, 614-20	4	136
658	Egg sharing for research: a successful outcome for patients and researchers. **2012**, 10, 239-40		12
657	The use of follicle flushing during oocyte retrieval in assisted reproductive technologies: a systematic review and meta-analysis. *Human Reproduction*, **2012**, 27, 2373-9	5.7	40
656	The poor responder in IVF: is the prognosis always poor?: a systematic review. **2012**, 18, 1-11		153

637 High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol. *Human Reproduction*, **2013**, 28, 442-52   5.7   51

636 Biennial Review of Infertility. **2013**,   1

635 Mild ovarian stimulation for in vitro fertilization: are we ready to change? A meta-analysis. **2013**, 76, 233-40   13

634 Endometrial scratching performed in the non-transfer cycle and outcome of assisted reproduction: a randomized controlled trial. **2013**, 42, 375-82   37

633 Relative contribution of advanced age and reduced follicle pool size on reproductive success. 318-329   1

632 Economic evaluation of highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone in fresh and frozen in vitro fertilization/intracytoplasmic sperm-injection cycles in Sweden. **2013**, 5, 381-97   10

631 Role of baseline antral follicle count and anti-Mullerian hormone in prediction of cumulative live birth in the first in vitro fertilisation cycle: a retrospective cohort analysis. **2013**, 8, e61095   58

630 Does the number of oocytes retrieved influence pregnancy after fresh embryo transfer?. **2013**, 8, e56189   27

629 Factors associated with failed treatment: an analysis of 121,744 women embarking on their first IVF cycles. **2013**, 8, e82249   56

628 Ultrasonography in Gynecology. 264-273   1

627 Comparisons of the effects of long-acting and short-acting GnRH agonists on embryo quality, endometrial thickness and pregnancy rate in human in vitro fertilization. **2014**, 10, 161-6   13

626 Número de folículos antrais e o sucesso da fertilização in vitro: uma análise multivariada. **2014**, 36, 473-479   3

625 International regulatory landscape and integration of corrective genome editing into in vitro fertilization. **2014**, 12, 108   85

624 Pharmacogenetics of ovarian response. **2014**, 15, 885-93   17

623 Role of baseline antral follicle count and anti-Mullerian hormone in the index stimulation cycle of IVF treatment in predicting outcome of subsequent frozen-thawed embryo transfers. *Gynecological Endocrinology*, **2014**, 30, 490-3   2.4   7

622 Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. *Human Reproduction*, **2014**, 29, 1688-97   5.7   41

621 Best protocol for controlled ovarian hyperstimulation in assisted reproductive technologies: fact or opinion?. **2014**, 32, 262-71   15

620 In vitro fertilization versus conversion to intrauterine insemination in Bologna-criteria poor responders: how to decide which option?. **2014**, 102, 1596-601   11

619 — Assisted Reproduction. **2014**, 734-773.e12 — 1

618 — The effects of prognostic factors on pregnancy success among women 39 years or older having intracytoplasmic sperm injection. **2014**, 11, 78-83

617 — AMH concentration is not related to effective time to pregnancy in women who conceive naturally. *Reproductive BioMedicine Online*, **2014**, 28, 216-24 — 4 — 42

616 — The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropin. *Gynecological Endocrinology*, **2014**, 30, 444-50 — 2.4 — 17

615 — Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in´vitro fertilization: a randomized controlled trial. **2014**, 101, 147-53 — 69

614 — Quality of embryos transferred and progesterone levels are the most important predictors of live birth after fresh embryo transfer: a retrospective cohort study. *Journal of Assisted Reproduction and Genetics*, **2014**, 31, 185-94 — 3.4 — 19

613 — Ovarian sensitivity index is a better measure of ovarian responsiveness to gonadotrophin stimulation than the number of oocytes during in-vitro fertilization treatment. *Journal of Assisted Reproduction and Genetics*, **2014**, 31, 199-203 — 3.4 — 27

612 — Value of antimüllerian hormone as a prognostic indicator of in´vitro fertilization outcome. **2014**, 101, 1012-8.e1 — 64

611 — Human Fertility. **2014**, — 3

610 — Association between response to ovarian stimulation and miscarriage following IVF: an analysis of 124 351 IVF pregnancies. *Human Reproduction*, **2014**, 29, 1218-24 — 5.7 — 53

609 — Change in oocyte yield in repeated in vitro fertilization cycles: effect of ovarian reserve. **2014**, 101, 399-402 — 12

608 — Impact of antimüllerian hormone assays on the outcomes of in´vitro fertilization: a prospective controlled study. **2014**, 101, 134-7 — 14

607 — Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. **2014**, 20, 124-40 — 295

606 — Investigations into implantation failure in oocyte-donation recipients. *Reproductive BioMedicine Online*, **2014**, 28, 99-105 — 4 — 14

605 — Is assessment of anti-Müllerian hormone and/or antral follicle count useful in the prediction of ovarian response in expected normal responders treated with a fixed dose of recombinant FSH and GnRH antagonists? A prospective observational study. *Gynecological Endocrinology*, **2014**, 30, 817-21 — 2.4 — 5

604 — Analysis of factors influencing morphokinetic characteristics of embryos in ART cycles. *Gynecological Endocrinology*, **2014**, 30 Suppl 1, 6-8 — 2.4 — 12

603 — Ovarian reserve screening: a scientific and ethical analysis. *Human Reproduction*, **2014**, 29, 2606-14 — 5.7 — 46

602 — Recombinant LH administration in subsequent cycle after "unexpected" poor response to recombinant FSH monotherapy. *Gynecological Endocrinology*, **2014**, 30, 813-6 — 2.4 — 11

601 [In vitro oocyte maturation for female fertility preservation]. **2014**, 42, 657-60 · 12

600 Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. **2014**, 20, 688-701 · 375

599 Live birth rates in Bologna poor responders treated with ovarian stimulation for IVF/ICSI. *Reproductive BioMedicine Online*, **2014**, 28, 469-74 · 4 · 81

598 Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. **2014**, 12, 17 · 86

597 Endometriosis. **2014**, · 4

596 The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. **2014**, 20, 560-70 · 154

595 Dehydroepiandrostendione sulphate and prediction of live birth after IVF in young women with low anti-Müllerian hormone concentration. *Reproductive BioMedicine Online*, **2014**, 28, 191-7 · 4 · 3

594 Preimplantation genetic diagnosis for inherited neurological disorders. **2014**, 10, 417-24 · 14

593 Pregnancy rates in donor oocyte cycles compared to similar autologous in vitro fertilization cycles: an analysis of 26,457 fresh cycles from the Society for Assisted Reproductive Technology. **2014**, 102, 399-404 · 32

592 Prediction models in in vitro fertilization; where are we? A mini review. **2014**, 5, 295-301 · 46

591 Impact of high serum progesterone during the late follicular phase on IVF outcome. *Reproductive BioMedicine Online*, **2014**, 29, 177-86 · 4 · 22

590 Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. **2014**, 101, 967-73 · 178

589 Ultrasonography in Gynecology. 233-237

588 Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles. **2015**, 13, 117 · 18

587 Strategies for Controlled Ovarian Stimulation in the Setting of Ovarian Aging. **2015**, 33, 436-48 · 4

586 Hohe Eizellzahl bei der IVF/ICSI. **2015**, 13, 195-196

585 Maximum basal FSH predicts reproductive outcome better than cycle-specific basal FSH levels: waiting for a "better" month conveys limited retrieval benefits. **2015**, 13, 91 · 9

584 Ovarian response is a better predictor of clinical pregnancy rate following embryo transfer than is thin endometrium or presence of an endometrioma. **2015**, 46, 501-5 · 14

565	Usability and utility of the CONSORT calculator for FSH starting doses: a prospective observational study. *Reproductive BioMedicine Online*, **2015**, 31, 347-55	4	8
564	Changing ovarian stimulation parameters in a subsequent cycle does not increase the number of euploid embryos. **2015**, 103, 947-53		3
563	Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. *Reproductive BioMedicine Online*, **2015**, 30, 248-57	4	35
562	Morphokinetic parameters of early embryo development via time lapse monitoring and their effect on embryo selection and ICSI outcomes: a prospective cohort study. *Journal of Assisted Reproduction and Genetics*, **2015**, 32, 563-70	3.4	36
561	Is the presence of a non-cleaved embryo on day 3 associated with poorer quality of the remaining embryos in the cohort?. *Journal of Assisted Reproduction and Genetics*, **2015**, 32, 677-83	3.4	6
560	Increased risk of preterm birth and low birthweight with very high number of oocytes following IVF: an analysis of 65 868 singleton live birth outcomes. *Human Reproduction*, **2015**, 30, 1473-80	5.7	80
559	Can you ever collect too many oocytes?. *Human Reproduction*, **2015**, 30, 81-7	5.7	47
558	Morphokinetics analysis of embryos derived from vitrified/warmed oocytes. *Journal of Assisted Reproduction and Genetics*, **2015**, 32, 1615-21	3.4	5
557	Controlled Ovarian Stimulation for Follicular Recruitment and Oocyte Recovery in IVF. **2015**, 21-31		
556	The past, present and future of fertility preservation in cancer patients. **2015**, 11, 2667-2680		5
555	Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles. **2015**, 104, 1145-52.e1-5		78
554	Optimum oocyte retrieved and transfer strategy in young women with normal ovarian reserve undergoing a long treatment protocol: a retrospective cohort study. *Journal of Assisted Reproduction and Genetics*, **2015**, 32, 1459-67	3.4	16
553	Is the time interval between HCG administration and oocyte retrieval associated with oocyte retrieval rate?. *Reproductive BioMedicine Online*, **2015**, 31, 625-32	4	8
552	Why more is less and less is more when it comes to ovarian stimulation. *Journal of Assisted Reproduction and Genetics*, **2015**, 32, 1713-9	3.4	12
551	Rescue of failed oocyte activation after ICSI in a mouse model of male factor infertility by recombinant phospholipase C**2015**, 21, 783-91		47
550	Minimal Stimulation and Natural Cycle In Vitro Fertilization. **2015**,		
549	The sub-optimal response to controlled ovarian stimulation: manageable or inevitable?. *Human Reproduction*, **2015**, 30, 2009-10	5.7	3
548	Assessing ovarian response: antral follicle count versus anti-Müllerian hormone. *Reproductive BioMedicine Online*, **2015**, 31, 486-96	4	135

547 Sub-optimal responders following controlled ovarian stimulation: an overlooked group?. *Human Reproduction*, **2015**, 30, 2005-8 — 5.7 — 59

546 Ovarian stimulation for oocyte cryopreservation for prevention of age-related fertility loss: one in five is a low responder. *Gynecological Endocrinology*, **2015**, 31, 779-82 — 2.4 — 16

545 Screening the Single Euploid Embryo. **2015**,

544 Antimüllerian hormone: prediction of cumulative live birth in gonadotropin-releasing hormone antagonist treatment for in vitro fertilization. **2015**, 104, 891-898.e2 — 27

543 Ectopic pregnancy rate increases with the number of retrieved oocytes in autologous in vitro fertilization with non-tubal infertility but not donor/recipient cycles: an analysis of 109,140 clinical pregnancies from the Society for Assisted Reproductive Technology registry. **2015**, 104, 873-878 — 16

542 Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone. *Human Reproduction*, **2015**, 30, 170-8 — 5.7 — 38

541 Urinary Phthalate Metabolite Concentrations and Reproductive Outcomes among Women Undergoing in Vitro Fertilization: Results from the EARTH Study. **2016**, 124, 831-9 — 128

540 Are there optimal numbers of oocytes, spermatozoa and embryos in assisted reproduction?. **2016**, 20, 142-9 — 9

539 Advantage of Genetic Modifications Using Genome Editing Technology in Stem Cells vs. Zygotes in Genetic Diseases. **2016**, 4,

538 Does Unilateral Oocyte Retrieval due to Transvaginally Inaccessible Ovaries, Contrary to Common Beliefs, Affect IVF/ICSI Treatment Outcomes That Much?. *BioMed Research International*, **2016**, 2016, 3687483 — 3

537 PIVET rFSH dosing algorithms for individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and avoidance of ovarian hyperstimulation syndrome. **2016**, 10, 2561-73 — 25

536 Twenty-First-Century Eugenics. **2016**, — 5

535 IVF outcomes in average- and poor-prognosis infertile women according to the number of embryos transferred. *Reproductive BioMedicine Online*, **2016**, 33, 370-5 — 4 — 9

534 Sleep, Circadian Rhythms, and Fertility. **2016**, 2, 206-217 — 18

533 Can we modify assisted reproductive technology practice to broaden reproductive care access?. **2016**, 105, 1138-1143 — 14

532 A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. **2016**, 203, 30-4 — 48

531 Freezing oocytes or embryos after controlled ovarian hyperstimulation in cancer patients: the state of the art. **2016**, 12, 1731-41 — 6

530 CRISPR/Cas9 genome editing new and old ethical issues arising from a revolutionary technology. **2016**, 10, 139-159 — 22

529	Is FMR1 CGG repeat length a predictor of in´vitro fertilization stimulation response or outcome?. **2016**, 105, 1537-1546.e8		7
528	Follicular fluid and urinary concentrations of phthalate metabolites among infertile women and associations with in vitro fertilization parameters. **2016**, 61, 142-50		64
527	What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation?. *Human Reproduction*, **2016**, 31, 1493-500	5.7	28
526	IVF in women of 45 years and older: the largest single center cohort to date. **2016**, 106, e35		
525	Live birth and perinatal outcomes following stimulated and unstimulated IVF: analysis of over two decades of a nationwide data. *Human Reproduction*, **2016**, 31, 2261-7	5.7	40
524	Preservaci de fertilidad en endometriosis: estado actual de conocimiento y papel del sistema pblico de salud. **2016**, 3, 119-127		1
523	Individualized follicle-stimulating hormone dosing and in´vitro fertilization outcome in agonist downregulated cycles: a systematic review. **2016**, 95, 1333-1344		9
522	Retrieval of larger oocyte cohorts maximizes in vitro fertilization (IVF) birth rates per cycle. **2016**, 106, e34-e35		1
521	Is there any effect of oocyte count retrieved in the OPU procedure on pregnancy outcomes?. **2016**, 36, 416-9		
520	Excellence in assisted reproductive technologies: clinical and laboratory perspectives. *Journal of Assisted Reproduction and Genetics*, **2016**, 33, 1259-1260	3.4	
519	Development of a new clinically applicable device for embryo evaluation which measures embryo oxygen consumption. *Human Reproduction*, **2016**, 31, 2321-30	5.7	27
518	Comment on "Biosimilar FSH preparations- are they identical twins or just siblings?". **2016**, 14, 63		1
517	A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial. *Human Reproduction*, **2017**, 32, 112-118	5.7	53
516	Standards of Care in infertility in Europe. **2016**,		2
515	Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study. **2016**, 207, 94-99		25
514	Predicting the chances of a live birth after one or more complete cycles of in vitro fertilisation: population based study of linked cycle data from 113 873 women. **2016**, 355, i5735		105
513	Pregnancy outcomes of blastocysts cultured overnight after thawing. **2016**, 293, 1347-56		4
512	Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART). **2016**, 14, 1		46

511	Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles. *Human Reproduction*, **2016**, 31, 1859-65	5.7	26
510	Cumulative live birth rates after one or more complete cycles of IVF: a population-based study of linked cycle data from 178,898 women. *Human Reproduction*, **2016**, 31, 572-81	5.7	80
509	Regimen of ovarian stimulation affects oocyte and therefore embryo quality. **2016**, 105, 560-570		52
508	MicroRNA Expression is Altered in Granulosa Cells of Ovarian Hyperresponders. *Reproductive Sciences*, **2016**, 23, 1001-10	3	11
507	Awareness of the effects of postponing motherhood among hospital gynecologists: is their knowledge sufficient to offer appropriate help to patients?. *Journal of Assisted Reproduction and Genetics*, **2016**, 33, 215-20	3.4	11
506	[Fertility preservation in women of the childbearing age: Indications and strategies]. **2016**, 45, 424-44		3
505	Is anti-Müllerian hormone associated with IVF outcomes in young patients with diminished ovarian reserve?. **2016**, 12, 185-92		9
504	Younger poor ovarian response women achieved better pregnancy results in the first three IVF cycles. *Reproductive BioMedicine Online*, **2016**, 32, 532-7	4	19
503	Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?. *Human Reproduction*, **2016**, 31, 370-6	5.7	196
502	Specific ranges of anti-Mullerian hormone and antral follicle count correlate to provide a prognostic indicator for IVF outcome. **2017**, 17, 51-59		17
501	GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study. **2017**, 17, 105-110		9
500	Which factors are most predictive for live birth after in´vitro fertilization and intracytoplasmic sperm injection (IVF/ICSI) treatments? Analysis of 100 prospectively recorded variables in 8,400 IVF/ICSI single-embryo transfers. **2017**, 107, 641-648.e2		82
499	The Ovarian Follicle of Cows as a Model for Human. **2017**, 127-144		8
498	Ovarian stimulation protocols for IVF: is more better than less?. *Reproductive BioMedicine Online*, **2017**, 34, 345-353	4	39
497	Revisiting the progesterone to oocyte ratio. **2017**, 107, 671-676.e2		13
496	[Does accumulation of oocytes benefit to women with poor ovarian reserve? No]. **2017**, 45, 183-184		
495	Blastocyst Development in a Single Medium Compared to Sequential Media: A Prospective Study With Sibling Oocytes. *Reproductive Sciences*, **2017**, 24, 1312-1318	3	10
494	Methods of controlled ovarian stimulation for embryo/oocyte cryopreservation in breast cancer patients. **2017**, 2, 47-59		8

| 493 | A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. *Reproductive BioMedicine Online*, **2017**, 34, 429-438 | 4 | 37 |

| 492 | Age is a major prognosticator in extremely low oocyte retrieval cycles. **2017**, 56, 175-180 | | 5 |

| 491 | Comparison of the morphokinetic parameters of embryos according to ovarian reserve in IVF cycles. *Gynecological Endocrinology*, **2017**, 33, 733-736 | 2.4 | 7 |

| 490 | State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature. **2017**, 57, 50-57 | | 37 |

| 489 | A randomized controlled trial comparing the efficacy and safety of two HMG preparations gaining their LH bioactivity from different HCG sources. *Reproductive BioMedicine Online*, **2017**, 35, 17-27 | 4 | 6 |

| 488 | A universal freeze all strategy: why it is not warranted. **2017**, 29, 136-145 | | 9 |

| 487 | Euploidy rates in donor egg cycles significantly differ between fertility centers. *Human Reproduction*, **2017**, 32, 743-749 | 5.7 | 71 |

| 486 | Management of ovarian stimulation for IVF: narrative review of evidence provided for World Health Organization guidance. *Reproductive BioMedicine Online*, **2017**, 35, 3-16 | 4 | 16 |

| 485 | Ovarian response to controlled ovarian hyperstimulation: what does serum FSH say?. *Human Reproduction*, **2017**, 32, 1701-1709 | 5.7 | 11 |

| 484 | Minimal or Mild Ovarian Stimulation for IVF: Overview. **2017**, 195-209 | | 1 |

| 483 | Non-equivalence of anti-Müllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing. *Human Reproduction*, **2017**, 32, 1710-1715 | 5.7 | 24 |

| 482 | Total number of oocytes and zygotes are predictive of live birth pregnancy in fresh donor oocyte in vitro fertilization cycles. **2017**, 108, 262-268 | | 21 |

| 481 | The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial. *Human Reproduction*, **2017**, 32, 811-819 | 5.7 | 24 |

| 480 | How many embryos should be transferred? A validated score to predict ongoing implantation rate. **2017**, 212, 30-36 | | 3 |

| 479 | Developments in IVF warrant the adoption of new performance indicators for ART clinics, but do not justify the abandonment of patient-centred measures. *Human Reproduction*, **2017**, 32, 1155-1159 | 5.7 | 20 |

| 478 | Relationship between phospholipase C-zeta, semen parameters, and chromatin status. **2017**, 63, 259-268 | | 17 |

| 477 | Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis. **2017**, | | 4 |

| 476 | [Does accumulation of oocytes benefit to women with poor ovarian reserve? Yes]. **2017**, 45, 180-182 | | 1 |

457	Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis. *Human Reproduction*, **2017**, 32, 2485-2495	5.7	48
456	Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder. *Human Reproduction*, **2017**, 32, 2506-2514	5.7	48
455	Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder. *Human Reproduction*, **2017**, 32, 2496-2505	5.7	69
454	Does cumulative live birth plateau beyond a certain ovarian response?. **2017**, 108, 943		6
453	How much variation in oocyte yield after controlled ovarian stimulation can be explained? A multilevel modelling study. **2017**, 2017, hox018		13
452	Correlation of serum anti-Mlerian hormone levels with positive in vitro fertilization outcome using a short agonist protocol. **2017**, 16, 161-170		
451	Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health. *Human Reproduction*, **2017**, 32, 1549-1555	5.7	7
450	Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A Meta-analysis. *Frontiers in Endocrinology*, **2017**, 8, 114	5.7	57
449	A Higher Ovarian Response after Stimulation for IVF Is Related to a Higher Number of Euploid Embryos. *BioMed Research International*, **2017**, 2017, 5637923	3	20
448	Outcomes and Recommendations of an Indian Expert Panel for Improved Practice in Controlled Ovarian Stimulation for Assisted Reproductive Technology. **2017**, 2017, 9451235		5
447	Impact of late-follicular phase elevated serum progesterone on cumulative live birth rates: is there a deleterious effect on embryo quality?. *Human Reproduction*, **2018**, 33, 860-868	5.7	52
446	What is new in the management of poor ovarian response in IVF?. **2018**, 30, 155-162		49
445	The end for individualized dosing in IVF ovarian stimulation? Reply to letters-to-the-editor regarding the OPTIMIST papers. *Human Reproduction*, **2018**, 33, 984-988	5.7	5
444	Sequential clomiphene/corifollitrophin alpha as a technique for mild controlled ovarian hyperstimulation in IVF: a proof of concept study. *Journal of Assisted Reproduction and Genetics*, **2018**, 35, 1047-1052	3.4	2
443	Poor ovarian response as a predictor for live birth in older women undergoing IVF. *Reproductive BioMedicine Online*, **2018**, 36, 435-441	4	12
442	Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). **2018**, 2, CD012693		48
441	Should we continue to measure endometrial thickness in modern-day medicine? The effect on live birth rates and birth weight. *Reproductive BioMedicine Online*, **2018**, 36, 416-426	4	31
440	The number of oocytes retrieved during IVF: a balance between efficacy and safety. *Human Reproduction*, **2018**, 33, 58-64	5.7	61

421	Are too many eggs truly too many?. **2018**, 110, 632-633		0
420	A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain. **2018**, 21, 1096-1101		5
419	Outcome of assisted reproductive technology in different subgroups of poor ovarian responders fulfilling the POSEIDON criteria. **2018**, 23, 399-403		3
418	Complications of assisted reproductive technology treatment and the factors influencing reproductive outcome. **2018**, 20, 177-186		2
417	Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with recombinant FSH plus recombinant LH vs. human menopausal gonadotropin for women undergoing IVF. **2018**, 16, 68		5
416	Mild IVF Stimulation. **2018**, 2-8		
415	Monitoring COS and HRT Cycles. **2018**, 20-24		
414	The Effect of Supraphysiological Estradiol on Pregnancy Outcomes Differs Between Women With PCOS and Ovulatory Women. **2018**, 103, 2735-2742		12
413	Efficacy and safety of Ding-Kun-Dan for female infertility patients with predicted poor ovarian response undergoing in vitro fertilization/intracytoplasmic sperm injection: study protocol for a randomized controlled trial. **2018**, 19, 124		5
412	Anti-mūlerian hormone levels are associated with live birth rates in ART, but the predictive ability of anti-mūlerian hormone is modest. **2018**, 225, 199-204		18
411	Cumulative live birth rates after IVF in patients with polycystic ovaries: phenotype matters. *Reproductive BioMedicine Online*, **2018**, 37, 163-171	4	26
410	Fertility Preservation: Current and Future Perspectives for Oncologic Patients at Risk for Iatrogenic Premature Ovarian Insufficiency. *BioMed Research International*, **2018**, 2018, 6465903	3	9
409	The association between the number of oocytes retrieved for IVF, perinatal outcome and obstetric complications. *Human Reproduction*, **2018**, 33, 1939-1947	5.7	16
408	Dosage of exogenous gonadotropins is not associated with blastocyst aneuploidy or live-birth rates in PGS cycles in Chinese women. *Human Reproduction*, **2018**, 33, 1875-1882	5.7	22
407	The Effect of Dose Adjustments in a Subsequent Cycle of Women With Suboptimal Response Following Conventional Ovarian Stimulation. *Frontiers in Endocrinology*, **2018**, 9, 361	5.7	26
406	Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria-The Why. *Frontiers in Endocrinology*, **2018**, 9, 461	5.7	64
405	A pharmacogenetic approach to improve low ovarian response: The role of CAG repeats length in the androgen receptor gene. **2018**, 227, 41-45		2
404	Advantages of cumulative pregnancy outcomes in freeze-all strategy in high responders - A case-control matching analysis of a large cohort. **2018**, 117, 676-684		11

403   Fertility Preservation in Endocrine Disorders during Transition for Girls. **2018**, 33, 128-148   1

402   Latent genital tuberculosis adversely affects the ovarian reserve in infertile women. *Human Reproduction*, **2018**, 33, 1262-1269   5.7   5

401   Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients. **2018**, 109, 968-979   23

400   Assisted Reproduction. **2019**, 779-822.e16   2

399   Fertility Preservation in Women. **2019**, 603-614

398   Investigating the effect of lifestyle risk factors upon number of aspirated and mature oocytes in in vitro fertilization cycles: Interaction with antral follicle count. **2019**, 14, e0221015   6

397   A Comparison of the Miscarriage and Live Birth Rate for Frozen Embryo Transfer According to Two Endometrial Preparations: Natural or Primed with Estrogens. **2019**, 01, 43-49   0

396   IVF outcomes of women with discrepancies between age and serum anti-Müllerian hormone levels. **2019**, 17, 58   13

395   Is there an association between oocyte number and embryo quality? A systematic review and meta-analysis. *Reproductive BioMedicine Online*, **2019**, 39, 751-763   4   18

394   Ovulationsinduktion und ovarielle Stimulation. **2019**, 1-27

393   Both high and low HCG day progesterone concentrations negatively affect live birth rates in IVF/ICSI cycles. *Reproductive BioMedicine Online*, **2019**, 39, 852-859   4   5

392   Associations between ambient air pollution and pregnancy rate in women who underwent in vitro fertilization in Shenyang, China. **2019**, 89, 130-135   17

391   Clinical pregnancy (CP) and live birth (LB) increase significantly with each additional fertilized oocyte up to nine, and CP and LB decline after that: an analysis of 15,803 first fresh in vitro fertilization cycles from the Society for Assisted Reproductive Technology registry. **2019**, 112, 520-526.e1   4

390   Controlled ovarian hyperstimulation (COH) parameters associated with euploidy rates in donor oocytes. **2019**, 62, 103707   6

389   Anti-Müllerian Hormone in Fertility Preservation: Clinical and Therapeutic Applications. **2019**, 13, 1179558119854755   14

388   The Development of Gonadotropins for Clinical Use in the Treatment of Infertility. *Frontiers in Endocrinology*, **2019**, 10, 429   5.7   42

387   Common Stimulation Regimens in Assisted Reproductive Technology. **2019**, 131-137

386   Association between the number of oocytes retrieved and neonatal outcomes after freeze-all IVF cycles. *Human Reproduction*, **2019**, 34, 1937-1947   5.7   2

385	Relationships between the antral follicle count, steroidogenesis, and secretion of follicle-stimulating hormone and anti-Müllerian hormone during follicular growth in cattle. **2019**, 17, 88		12
384	Contribution of cryopreservation to the cumulative live birth rate: a large multicentric cycle-based data analysis from the Italian National Registry. *Journal of Assisted Reproduction and Genetics*, **2019**, 36, 2287-2295	3.4	5
383	The number of oocytes associated with maximum cumulative live birth rates per aspiration depends on female age: a population study of 221 221 treatment cycles. *Human Reproduction*, **2019**, 34, 1778-1787	5.7	25
382	Live birth rate is associated with oocyte yield and number of biopsied and suitable blastocysts to transfer in preimplantation genetic testing (PGT) cycles for monogenic disorders and chromosomal structural rearrangements. **2019**, 4, 100055		9
381	Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation. *Human Reproduction*, **2019**, 34, 2027-2035	5.7	12
380	Management Strategies for POSEIDON Groups 3 and 4. *Frontiers in Endocrinology*, **2019**, 10, 614	5.7	23
379	Dual stimulation using corifollitropin alfa in 54 Bologna criteria poor ovarian responders - a case series. *Reproductive BioMedicine Online*, **2019**, 38, 677-682	4	22
378	Estimation of age-dependent decrease in blastocyst euploidy by next generation sequencing: development of a novel prediction model. **2019**, 61, 3-10		29
377	Novel approaches for diagnosis and management of low prognosis patients in assisted reproductive technology: the POSEIDON concept. **2019**, 61, 24-29		31
376	Reply: Ovarian response and its prediction are relevant. *Human Reproduction*, **2019**, 34, 586-587	5.7	
375	A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany. **2019**, 11, 319-331		3
374	Cumulative live birth rates in low-prognosis women. *Human Reproduction*, **2019**, 34, 1030-1041	5.7	41
373	Antral follicle responsiveness assessed by follicular output RaTe(FORT) correlates with follicles diameter. **2019**, 12, 48		7
372	In Freeze-All Strategy, Cumulative Live Birth Rate (CLBR) Is Increasing According to the Number of Blastocysts Formed in Women . *Frontiers in Endocrinology*, **2019**, 10, 427	5.7	8
371	Different anti-Müllerian hormone (AMH) levels respond to distinct ovarian stimulation methods in assisted reproductive technology (ART): Clues to better ART outcomes. *Reproductive Medicine and Biology*, **2019**, 18, 263-272	4.1	5
370	Do female age and body weight modify the effect of individualized FSH dosing in IVF/ICSI treatment? A secondary analysis of the OPTIMIST trial. **2019**, 98, 1332-1340		2
369	Management of Women With an Unexpected Low Ovarian Response to Gonadotropin. *Frontiers in Endocrinology*, **2019**, 10, 387	5.7	30
368	Individualization of FSH Doses in Assisted Reproduction: Facts and Fiction. *Frontiers in Endocrinology*, **2019**, 10, 181	5.7	15

367   The incidence of unexpected poor ovarian response in Chinese young women. **2019**, 98, e14379   3

366   Is corifollitropin alfa effective in controlled ovarian stimulation among all poor ovarian responders? A retrospective comparative study. *Gynecological Endocrinology*, **2019**, 35, 894-898   2.4   3

365   An Observational Retrospective Cohort Trial on 4,828 IVF Cycles Evaluating Different Low Prognosis Patients Following the POSEIDON Criteria. *Frontiers in Endocrinology*, **2019**, 10, 282   5.7   16

364   Endometrial preparation before the transfer of single, vitrified-warmed, euploid blastocysts: does the duration of estradiol treatment influence clinical outcome?. **2019**, 111, 1177-1185.e3   11

363   Do poor-responder patients undergoing IVF benefit from splitting and increasing the daily gonadotropin dose?. *Gynecological Endocrinology*, **2019**, 35, 890-893   2.4   2

362   A Novel Predictive Model to Estimate the Number of Mature Oocytes Required for Obtaining at Least One Euploid Blastocyst for Transfer in Couples Undergoing Fertilization/Intracytoplasmic Sperm Injection: The ART Calculator. *Frontiers in Endocrinology*, **2019**, 10, 99   5.7   39

361   Anti-Müllerian Hormone Gene Polymorphism is Associated with Clinical Pregnancy of Fresh IVF Cycles. **2019**, 16,   2

360   Natural Cycle and Minimal Stimulation IVF. **2019**, 49-58

359   The Gonadotropins in IVF. **2019**, 69-79

358   Oocyte Recovery. **2019**, 127-140

357   The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis. **2019**, 17, 18   27

356   Ultrasonographically diagnosed dermoid cysts do not influence ovarian stimulation response in an fertilization cycle. *Gynecological Endocrinology*, **2019**, 35, 612-617   2.4   1

355   Advanced Maternal Age in IVF: Still a Challenge? The Present and the Future of Its Treatment. *Frontiers in Endocrinology*, **2019**, 10, 94   5.7   47

354   Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response. *Human Reproduction*, **2019**, 34, 530-538   5.7   12

353   Human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate. *Reproductive BioMedicine Online*, **2019**, 38, 908-915   4   38

352   Anti-Müllerian Hormone and Its Predictive Utility in Assisted Reproductive Technologies Outcomes. **2019**, 62, 238-256   5

351   The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists. *Frontiers in Endocrinology*, **2019**, 10, 814   5.7   40

350   Screening Human Embryos for Polygenic Traits Has Limited Utility. **2019**, 179, 1424-1435.e8   34

349	Diminished ovarian reserve versus ovarian aging: overlaps and differences. **2019**, 31, 139-147		19
348	The impact of follicle-flushing during oocyte collection on embryo development of in-vitro fertilization. **2019**, 17, 106		0
347	Larger oocyte cohorts maximize fresh IVF cycle birth rates and availability of surplus high-quality blastocysts for cryopreservation. *Reproductive BioMedicine Online*, **2019**, 38, 711-723	4	9
346	Cumulative live birth rate prognosis based on the number of aspirated oocytes in previous ART cycles. *Human Reproduction*, **2019**, 34, 171-180	5.7	20
345	How time to healthy singleton delivery could affect decision-making during infertility treatment: a Delphi consensus. *Reproductive BioMedicine Online*, **2019**, 38, 118-130	4	12
344	Is more better? A higher oocyte yield is independently associated with more day-3 euploid embryos after ICSI. *Human Reproduction*, **2019**, 34, 79-83	5.7	10
343	Prediction of the lower serum anti-Müllerian hormone threshold for ovarian stimulation prior to in-vitro fertilization using the Elecsys AMH assay: a prospective observational study. **2019**, 17, 11		6
342	The effect of performing hysteroscopy prior to the first in vitro fertilization (IVF) cycle on live birth rate. *Gynecological Endocrinology*, **2019**, 35, 443-447	2.4	2
341	Chemotherapy-related damage to ovarian reserve in childhood cancer survivors: interpreting the evidence. *Journal of Assisted Reproduction and Genetics*, **2019**, 36, 341-348	3.4	6
340	Endometrial but not Ovarian Response is Associated With Clinical Outcomes and can be Improved by Prolonged Pituitary Downregulation in Patients With Thin and Medium Endometrium. *Reproductive Sciences*, **2019**, 26, 1409-1416	3	9
339	Towards complication-free assisted reproduction technology. **2019**, 33, 9-19		3
338	The role of stimulation protocol, number of oocytes retrieved with respect to follicular fluid oxidative stress and IVF outcome. **2020**, 23, 23-31		2
337	Contribution of rescue in-vitro maturation versus double ovarian stimulation in ovarian stimulation cycles of poor-prognosis women. *Reproductive BioMedicine Online*, **2020**, 40, 511-517	4	5
336	Ovarian stimulation for freeze-all IVF cycles: a systematic review. **2020**, 26, 118-135		27
335	Effect of deprivation on in vitro fertilisation outcome: a cohort study. **2020**, 127, 458-465		6
334	Individualized ovarian stimulation in IVF/ICSI treatment: it is time to stop using high FSH doses in predicted low responders. *Human Reproduction*, **2020**, 35, 1954-1963	5.7	13
333	Influence of stage and grade of breast cancer on fertility preservation outcome in reproductive-aged women. *Reproductive BioMedicine Online*, **2020**, 40, 215-222	4	3
332	Is it possible to apply trial outcomes to a real-world population? A novel approach to External Validity Analysis. **2020**, 60, 284-289		0

331   Haste makes waste: don't rush for a fresh embryo transfer in high responders. *Human Reproduction*, **2020**, 35, 2660-2662   5.7   1

330   DuoStim: a new option for fertility preservation for a woman with Turner syndrome. *Gynecological Endocrinology*, **2020**, 36, 1144-1148   2.4   1

329   IVF, from the past to the future: the inheritance of the Capri Workshop Group. **2020**, 2020, hoaa040   5

328   A comparison of IVF outcomes transferring a single ideal blastocyst in women with polycystic ovary syndrome and normal ovulatory controls. **2020**, 302, 1479-1486   5

327   Ovarian hyperstimulation syndrome after assisted reproductive technologies: trends, predictors, and pregnancy outcomes. **2020**, 114, 567-578   6

326   Gonadotropin-releasing hormone agonist combined with hormone replacement therapy does not improve the reproductive outcomes of frozen-thawed embryo transfer cycle in elderly patients: a retrospective study. **2020**, 18, 73   6

325   The Relationship Between Serum Delta FSH Level and Ovarian Response in IVF/ICSI Cycles. *Frontiers in Endocrinology*, **2020**, 11, 536100   5.7   1

324   Comparative Effectiveness of Mild or Conventional GnRH-Antagonist Protocols for Ovarian Stimulation in Poor Responders (Poseidon Group 4). **2020**, 2,

323   Sperm source does not affect the ICSI outcome of patients with severely compromised spermatogenesis. **2020**, 52, e13884   1

322   Influence of human chorionic gonadotrophin during ovarian stimulation: an overview. **2020**, 18, 80   3

321   A visualized clinical model predicting good quality blastocyst development in the first IVF/ICSI cycle. *Reproductive BioMedicine Online*, **2020**, 41, 807-817   4   0

320   The role of diet in unexpected poor response to ovarian stimulation: a cross-sectional study. *Reproductive BioMedicine Online*, **2020**, 41, 874-883   4   2

319   Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis. **2020**, 10, 574669   14

318   Defining critical factors in multi-country studies of assisted reproductive technologies (ART): data from the US and UK health systems. *Journal of Assisted Reproduction and Genetics*, **2020**, 37, 2767-2775   3.4

317   Should we still offer elective freezing of all embryos in all IVF cycles?. *Human Reproduction*, **2020**, 35, 2179-2184   5.7   2

316   SAY NO to mild ovarian stimulation for all poor responders: it is time to realize that not all poor responders are the same. *Human Reproduction*, **2020**, 35, 1964-1971   5.7   7

315   Initial ovarian sensitivity index predicts embryo quality and pregnancy potential in the first days of controlled ovarian stimulation. **2020**, 13, 94   1

314   Clinical Application of AMH Measurement in Assisted Reproduction. *Frontiers in Endocrinology*, **2020**, 11, 606744   5.7   2

313	Fertility Preservation in Women: Indications and Options for Therapy. **2020**, 95, 770-783		8
312	Are we looking under the lamp although we know the lost key is somewhere else? Or is it just about the egg?. **2020**, 125, 200-203		0
311	Is the probability of pregnancy after ovarian stimulation for IVF associated with serum estradiol levels on the day of triggering final oocyte maturation with hCG? A systematic review and meta-analysis. *Journal of Assisted Reproduction and Genetics*, **2020**, 37, 1531-1541	3.4	1
310	Inhibin A-A Promising Predictive Parameter for Determination of Final Oocyte Maturation in Ovarian Stimulation for IVF/ICSI. *Frontiers in Endocrinology*, **2020**, 11, 307	5.7	2
309	Stop GnRH-Agonist Combined With Multiple-Dose GnRH-Antagonist Protocol for Patients With "Genuine" Poor Response Undergoing Controlled Ovarian Hyperstimulation for IVF. *Frontiers in Endocrinology*, **2020**, 11, 182	5.7	2
308	Outcomes of ovarian stimulation and fertility preservation in breast cancer patients with different hormonal receptor profiles. *Journal of Assisted Reproduction and Genetics*, **2020**, 37, 913-921	3.4	6
307	Effect of oocyte donor stimulation on recipient outcomes: data from a US national donor oocyte bank. *Human Reproduction*, **2020**, 35, 847-858	5.7	8
306	Management Strategies for POSEIDON Group 2. *Frontiers in Endocrinology*, **2020**, 11, 105	5.7	5
305	Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations. **2020**, 21,		11
304	The Ovarian Sensitivity Index (OSI) Significantly Correlates with Ovarian Reserve Biomarkers, Is More Predictive of Clinical Pregnancy than the Total Number of Oocytes, and Is Consistent in Consecutive IVF Cycles. **2020**, 9,		4
303	Stop GnRH-Agonist Combined with Multiple-Dose GnRH-Antagonist for Patients with Elevated Peak Serum Progesterone Levels Undergoing Ovarian Stimulation for IVF: A Proof of Concept. **2020**, 85, 357-361		2
302	Impact of elective frozen vs. fresh embryo transfer strategies on cumulative live birth: Do deleterious effects still exist in normal & hyper responders?. **2020**, 15, e0234481		6
301	Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization. **2020**, 13,		6
300	Equivalent live-birth rate in antagonist IVF/ICSI protocol after oocyte triggering with GnRH agonist supplemented with 1500 r-hCG the day of oocyte retrieval vs r-hCG : A case-control study. **2020**, 49, 101702		
299	Validation of ART Calculator for Predicting the Number of Metaphase II Oocytes Required for Obtaining at Least One Euploid Blastocyst for Transfer in Couples Undergoing Fertilization/Intracytoplasmic Sperm Injection. *Frontiers in Endocrinology*, **2019**, 10, 917	5.7	16
298	Growth Hormone Supplementation May Not Improve Live Birth Rate in Poor Responders. *Frontiers in Endocrinology*, **2020**, 11, 1	5.7	48
297	A mediation analysis for a nonrare dichotomous outcome with sequentially ordered multiple mediators. **2020**, 39, 1415-1428		1
296	Impact of extent and biochemical parameters of lymphoma on fertility preservation outcome. **2020**, 113, 400-407.e1		

277	Maternal age affects the relationship of basal FSH and anti-Müllerian hormone concentrations with post-ICSI/IVF live birth. *Reproductive BioMedicine Online*, **2021**, 42, 748-756	4	2
276	Is There Any Association Between the Number of Oocytes Retrieved, Women Age, and Embryo Development?. *Reproductive Sciences*, **2021**, 28, 1890-1900	3	2
275	DuoStim cycles potentially boost reproductive outcomes in poor prognosis patients. *Gynecological Endocrinology*, **2021**, 37, 519-522	2.4	1
274	Can Ratios Between Prognostic Factors Predict the Clinical Pregnancy Rate in an IVF/ICSI Program with a GnRH Agonist-FSH/hMG Protocol? An Assessment of 2421 Embryo Transfers, and a Review of the Literature. *Reproductive Sciences*, **2021**, 28, 495-509	3	
273	Oocyte recovery rates in flushing versus nonflushing during oocyte retrieval in assisted reproductive techniques. *Fertility Science and Research*, **2021**, 8, 36	0.1	
272	Predicting the outcomes of assisted reproductive technology treatments: a systematic review and quality assessment of prediction models. **2021**, 2, 1-10	0	
271	How does pathology influence cumulative pregnancy rate in poor responder patients?. **2021**, 1, 23		
270	Dietary pattern characterisation among subfertile South Asian women and the impact of vitamin B12 intake on frozen embryo transfer outcomes: a cross-sectional study. **2021**, 2021, hoaa068	0	
269	OOSİT İKİLİNİN İGRİMESİ Kontrollü Ovaryan Hiperstimulasyon sikluslarında folikülerden kan oosit sayısını hastı maksimize edebiliriz?.		
268	Type and dose of gonadotropins in poor ovarian responders: does it matter?. **2021**, 15, 26334941211024203	0	
267	Practical Clinical and Diagnostic Pathway for the Investigation of the Infertile Couple. *Frontiers in Endocrinology*, **2020**, 11, 591837	5.7	6
266	POSEIDON classification and the proposed treatment options for groups 1 and 2: time to revisit? A retrospective analysis of 1425 ART cycles. **2021**, 2021, hoaa070	0	
265	The POSEIDON stratification - moving from poor ovarian response to low prognosis. **2021**, 25, 282-292	2	
264	A Novel Stimulation Protocol for Poor-Responder Patients: Combining the Stop GnRH-ag Protocol with Letrozole Priming and Multiple-Dose GnRH-ant: A Proof of Concept. **2021**, 86, 149-154	2	
263	Efficacy of growth hormone supplementation with ultrashort GnRH antagonist in IVF/ICSI for poor responders; randomized controlled trial. **2021**, 60, 51-55	3	
262	Mitochondrial enrichment in infertile patients: a review of different mitochondrial replacement therapies. **2021**, 15, 26334941211023544	5	
261	Double or dual stimulation in poor ovarian responders: where do we stand?. **2021**, 15, 26334941211024172	3	
260	The impact of preovulatory versus midluteal serum progesterone level on live birth rates during fresh embryo transfer. **2021**, 16, e0246440	1	

259	Cleavage vs blastocyst stage embryos: how are they interrelating?. **2021**, 304, 1083-1088		
258	Does quantity equal quality?-A morphokinetic assessment of embryos obtained from young women with decreased ovarian response to controlled ovarian stimulation. *Journal of Assisted Reproduction and Genetics*, **2021**, 38, 1115-1122	3.4	0
257	Clinical Applications of Serum Anti-Müllerian Hormone Measurements in Both Males and Females: An Update. **2021**, 2, 100091		3
256	Clinical Outcomes of Frozen-Thawed Embryos Generated From Growth Hormone Stimulation in Expected Poor Responders. *Frontiers in Endocrinology*, **2020**, 11, 608225	5.7	
255	Future fertility of patients with zero oocytes yield in their first IVF cycle attempt. **2021**, 16, e0246889		0
254	Luteal Support with very Low Daily Dose of Human Chorionic Gonadotropin after Fresh Embryo Transfer as an Alternative to Cycle Segmentation for High Responders Patients Undergoing Gonadotropin-Releasing Hormone Agonist-Triggered IVF. **2021**, 14,		0
253	Improving Reporting of Clinical Studies Using the POSEIDON Criteria: POSORT Guidelines. *Frontiers in Endocrinology*, **2021**, 12, 587051	5.7	3
252	AMH Highly Correlates With Cumulative Live Birth Rate in Women with Diminished Ovarian Reserve Independent of Age. **2021**, 106, 2754-2766		7
251	Individualized Oocyte Maturation. **2021**, 30-38		
250	Do we trust scientific evidence? A multicentre retrospective analysis of first IVF/ICSI cycles before and after the OPTIMIST trial. *Human Reproduction*, **2021**, 36, 1367-1375	5.7	2
249	Pasado presente y futuro de la estimulación ovárica en el tratamiento de la infertilidad. **2021**, 32, 173-179		1
248	Individualized Ovarian Stimulation for Normal and High Responders. **2021**, 1-13		
247	Do follicular fluid advanced glycation end products levels affect the ovarian response in unexplained infertility?. *Gynecological Endocrinology*, **2021**, 37, 802-806	2.4	1
246	Optimal Oocyte Number in Controlled Ovarian Stimulation with Gonadotropin-Releasing Hormone Agonist/Antagonist and Day 3 Fresh Embryo Transfer. *Reproductive Sciences*, **2021**, 28, 2861-2868	3	0
245	Endometrial scratching for poor responders based on the Bologna criteria in ICSI fresh embryo transfer cycles: a preliminary retrospective cohort study. **2021**, 22, 47-52		
244	Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis. **2021**, 19, 51		0
243	FSH dose is negatively correlated with number of oocytes retrieved: analysis of a data set with ~650,000 ART cycles that previously identified an inverse relationship between FSH dose and live birth rate. *Journal of Assisted Reproduction and Genetics*, **2021**, 38, 1787-1797	3.4	3
242	The effect of polymorphisms in FSHR and FSHB genes on ovarian response: a prospective multicenter multinational study in Europe and Asia. *Human Reproduction*, **2021**, 36, 1711-1721	5.7	5

241	Consecutive ovarian stimulation is beneficial in patients with a poor response to high-dose follicle-stimulating hormone. *Gynecological Endocrinology*, **2021**, 37, 995-999	2.4	
240	Effect of Dexamethasone Co-Treatment During Ovarian Stimulation in Women of Different Reproductive Age With Elevated Early Follicular Phase Progesterone Level: a Prospective Longitudinal Study. *Reproductive Sciences*, **2021**, 28, 3258-3264	3	
239	Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus. *Frontiers in Endocrinology*, **2021**, 12, 675670	5.7	5
238	The Impact of High-Normal TSH Levels on Reproductive Outcomes in Women Undergoing ART Treatment: a Systematic Review and Meta-analysis. *Reproductive Sciences*, **2021**, 1	3	0
237	ART outcomes following ovarian stimulation in the luteal phase:a systematic review and meta-analysis. *Journal of Assisted Reproduction and Genetics*, **2021**, 38, 1927-1938	3.4	0
236	Comparison of Cumulative Live Birth Rates Between GnRH-A and PPOS in Low-Prognosis Patients According to POSEIDON Criteria: A Cohort Study. *Frontiers in Endocrinology*, **2021**, 12, 644456	5.7	0
235	Analysis of related factors affecting cumulative live birth rates of the first ovarian hyperstimulation in vitro fertilization or intracytoplasmic sperm injection cycle: a population-based study from 17,978 women in China. **2021**, 134, 1405-1415		0
234	Poor response during ovarian stimulation. 271-278		
233	The couple with recurrent implantation failure. **2021**, 200-206		
232	A decision tree model for predicting live birth in FMR1 premutation carriers undergoing preimplantation genetic testing for monogenic/single gene defects. *Reproductive BioMedicine Online*, **2021**, 43, 680-686	4	1
231	Editorial: POSEIDON's Stratification of 'Low Prognosis' Patients in ART: The WHY, the WHAT, and the HOW. *Frontiers in Endocrinology*, **2021**, 12, 719647	5.7	
230	The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART. **2021**, 2021, hoab022		8
229	Study design flaws and statistical challenges in evaluating fertility treatments.. **2021**, 2, C9-C21		0
228	Predictive value of the number of frozen blastocysts in live birth rates of the transferred fresh embryos. **2021**, 14, 83		1
227	Unexpected drop in the IVF clinic pregnancy rate. **2021**, 690-695		
226	Endometrial and follicular development following stair-step and traditional protocols in women with polycystic ovary syndrome: An RCT. **2021**, 19, 537-544		
225	The circulating alarin level was elevated in infertile women with poor ovarian reserve. *Gynecological Endocrinology*, **2021**, 37, 1128-1131	2.4	1
224	A Randomized Controlled Trial on the Efficacy and Safety of Low-Dose hCG in a Short Protocol with GnRH Agonist and Ovarian Stimulation with Recombinant FSH (rFSH) During the Follicular Phase in Infertile Women Undergoing ART. *Reproductive Sciences*, **2021**, 1	3	0

223	Gonadotrophin stimulation reduces follicular fluid hormone concentrations and disrupts their quantitative association with cumulus cell mRNA. *Reproductive BioMedicine Online*, **2021**,	4	3
222	Prediction of Ovarian Follicular Dominance by MRI Phenotyping of Hormonally Induced Vascular Remodeling. **2021**, 8, 711810		
221	Oocyte or embryo number needed to optimize live birth and cumulative live birth rates in mild stimulation IVF cycles. *Reproductive BioMedicine Online*, **2021**, 43, 223-232	4	3
220	The endocrine milieu in naturally matured follicles is different in women with high serum anti-Müllerian hormone concentrations. *Reproductive BioMedicine Online*, **2021**, 43, 329-337	4	3
219	Blastocyst versus cleavage transfers: who benefits?. **2021**, 1		2
218	A Novel Nomogram for Individualized Gonadotropin Starting Dose in GnRH Antagonist Protocol. *Frontiers in Endocrinology*, **2021**, 12, 688654	5.7	0
217	Testosterone does not improve ovarian response in Bologna poor responders: a randomized controlled trial (TESTOPRIM). *Reproductive BioMedicine Online*, **2021**, 43, 466-474	4	0
216	Random antral follicle count performed on any day of the menstrual cycle has the same predictive value as AMH for good ovarian response in IVF cycles. **2021**, 51, 102233		
215	Fertilization rate as a novel indicator for cumulative live birth rate: a multicenter retrospective cohort study of 9,394 complete in´vitro fertilization cycles. **2021**, 116, 766-773		3
214	Follicular flushing using double lumen needle yields more oocytes in mono-follicular poor responders. **2021**, 50, 102150		1
213	Reproduktionsmedizinische Techniken: Indikationen, Durchführung und Chancen (VZO, IUI, IVF, ICSI). **2021**, 1-17		
212	A Histopathological Evaluation of Ovarian Hyperstimulation Syndrome on Reproductive and Vital Organs and the Role of the VEGF-PKA Pathway in a Mouse Model. **2021**, 210, 218-238		
211	Fresh and cumulative live birth rates in mild versus conventional stimulation for IVF cycles in poor ovarian responders: a systematic review and meta-analysis. **2021**, 2021, hoaa066		5
210	Cumulative live birth rates of patients in the Peruvian Andes according to the POSEIDON criteria: a single-center retrospective analysis. **2021**, 25, 412-416		
209	Freeze-all policy for in vitro fertilization in women with normal response to ovarian stimulation. **2021**, 19, eAO6290		
208	Ovarian stimulation for IVF: mild approaches. **2014**, 1154, 305-28		8
207	Ovulationsinduktion und ovarielle Stimulation. **2020**, 115-141		1
206	Cumulative live birth rate of low prognosis patients with POSEIDON stratification: a single-centre data analysis. *Reproductive BioMedicine Online*, **2020**, 41, 834-844	4	2

| 205 | Utility of polygenic embryo screening for disease depends on the selection strategy. | 3 |

| 204 | Ovarian biomarkers predict controlled ovarian stimulation for in vitro fertilisation treatment in Singapore. **2020**, 61, 463-468 | 3 |

| 203 | Basics of Ovarian Stimulation. **2017**, 55-72 | 1 |

| 202 | Clinical Considerations of Preimplantation Genetic Diagnosis for Monogenic Diseases. **2015**, 10, e0139613 | 7 |

| 201 | Ovarian stimulation for preimplantation genetic testing. **2019**, 157, R127-R142 | 2 |

| 200 | Morphological evaluation of human oocytes in IVF practice (a review). **2017**, 23, 54 | 1 |

| 199 | Effect of Genital Tuberculosis on Ovarian Reserve. **2020**, 16, 104 | 1 |

| 198 | Vitrification has detrimental effects on maturation, viability, and subcellular quality of oocytes post IVM in cancerous women: An experimental study. **2019**, 17, | 2 |

| 197 | Efficacy and safety of recombinant human follicle-stimulating hormone in patients undergoing fertilization-embryo transfer. **2020**, 12, 4918-4930 | 3 |

| 196 | Statistical Modelling Outcome of In Vitro Fertilization and Intracytoplasmic Sperm Injection: A Single Centre Study. **2019**, 22, 225-231 | 0 |

| 195 | Cumulative live birth rates in in-vitro fertilization. **2019**, 71, 207-210 | 16 |

| 194 | Predictive Factors for Live Birth in Autologous in Vitro Fertilization Cycles in Women Aged 40 Years and Older. **2019**, 58, 173-178 | 1 |

| 193 | Comparative Study of Serum Progesterone Levels at the Time of Human Chorionic Gonadotropin Trigger and Ovum PickUp in Predicting Outcome in Fresh Fertilization Cycles. **2019**, 12, 234-239 | 1 |

| 192 | Evaluating the Utility of Intralipid Infusion to Improve Live Birth Rates in Patients with Recurrent Pregnancy Loss or Recurrent Implantation Failure. **2018**, 11, 261-268 | 16 |

| 191 | High Progesterone levels in the beginning of ICSI antagonist cycles and clinical pregnancy: still a concern?. **2017**, 21, 11-14 | 5 |

| 190 | FSH dose to stimulate different patient' ages: when less is more. **2017**, 21, 336-342 | 10 |

| 189 | Serum microRNA profiling for the identification of predictive molecular markers of the response to controlled ovarian stimulation. **2020**, 24, 97-103 | 1 |

| 188 | Utility of polygenic embryo screening for disease depends on the selection strategy. **2021**, 10, | 6 |

187   Extended Injection Intervals of Gonadotropins by Intradermal Administration in IVF Treatment. **2021**,   2

186   Ovarian Folliculogenesis and Uterine Endometrial Receptivity after Intermittent Vaginal Injection of Recombinant Human Follicle-Stimulating Hormone in Infertile Women Receiving In Vitro Fertilization and in Immature Female Rats. **2021**, 22,   3

185   A decision tree analysis applied to women aged 43-45: who should be referred for ovum donation?. *Reproductive BioMedicine Online*, **2021**,   4   0

184   Correlation analysis of clinical and medical history records of married couples receiving infertility treatment. **2021**, 84-93

183   Development and Validation of Prediction Model for High Ovarian Response in Fertilization-Embryo Transfer: A Longitudinal Study. **2021**, 2021, 7822119   1

182   Poor Response during Ovarian Stimulation. 169-174

181   Ovarielle Stimulation. **2013**, 109-136

180   Oocyte vitrification: A local validation of the method. **2013**, 03, 6-10

179   Patient-Tailored Approaches to Ovarian Stimulation in ART. **2013**, 137-153

178   Physiologie der Befruchtung. **2013**, 73-80

177   Trial of Assisted Reproductive Technology with Sperm Cryopreservation in Nihon University Itabashi Hospital. **2014**, 73, 150-153

176   Ovarian Reserve in Patients with Endometriosis. **2014**, 419-429

175   Lessons Learned and Future Challenges. **2015**, 95-101

174   Sequential Use of Testosterone Gel and Growth Hormone in Expected Poor Responders and those with Previous Poor Assisted Reproductive Technology Outcomes: A Pilot Study. **2017**, 8, 1-4   1

173   Standard Ovarian Stimulation Protocols and Their Outcomes. **2017**, 129-146

172   Clinical analyses of successful and previously failed intracytoplasmic sperm injection cycle parameters in patients with poor ovarian reserve. **2017**, 14, 58-63

171   Testing Ovarian Reserve. **2017**, 43-54

170   Physiologie der Befruchtung. **2018**, 1-8

169   Physiologie der Befruchtung. **2018**, 1-8

168   Dık Over Rezervli Hastalarda GnRH Antagonist/Letrozol Stimılasyon Protokolını Kullanılmasının İntrasitoplazmik Sperm Enjeksiyonu Siklus Sonuçlarına Etkisi. **2018**, 44, 13-17

167   Ovarian Stimulation Protocols. 231-240

166   Estimulaciın ovırica para fecundaciın in vitro-inyecciın intracitoplasmırica de espermatozoides en los ciclos con presunciın de alta respuesta (2017). **2019**,

165   Comparison of the effectiveness of various stimulation protocols in patients with reduced ovarian reserve. **2019**, 25, 91   0

164   Modelos predictivos en reproducciın asistida: revisiın sistemırica y anırisis crırico. **2019**, 6, 63-74

163   Screening human embryos for polygenic traits has limited utility.

162   Patient and in vitro fertilization (IVF) cycle characteristics associated with variable blastulation rates: a retrospective study from the Duke Fertility Center (2013ロ2017). **2020**, 24,   1

161   Monitoring Follicular Growth. **2020**, 121-139

160   Physiologie der Befruchtung. **2020**, 79-85

159   Outcomes in poor responders treated with in vitro fertilization/intracytoplasmic sperm injection according to bologna criteria. **2019**, 47-50

158   Effectiveness and Safety of Freeze-All Strategy with Regard to Medically Assisted Reproduction and Perinatal Outcomes. **2020**, 411-418

157   The ovarian sensitivity index is predictive of live birth chances after IVF in infertile patients. **2020**, 2020, hoaa049   3

156   Assisted Reproductive Technologies. **2020**, 263-284   1

155   Embryo donation among Latin-Americans who have attended assisted reproduction techniques: a first empirical approach. **2021**, 25, 81-89

154   Does the Freeze-all strategy improve the cumulative live birth rate and the time to become pregnant in IVF cycles?.

153   Reintroducing serum FSH measurement during ovarian stimulation for ART.. *Reproductive BioMedicine Online*, **2021**,   4

152   Randomised controlled trial on the effect of clomiphene citrate and gonadotropin dose on ovarian response markers and IVF outcomes in poor responders. *Human Reproduction*, **2021**, 36, 987-997   5.7   4

151   Anti-Müllerian Hormone: A Personal View of the Empowering Analyte. **2020**, 13, 257-260   0

150   Factors related to infertility in Brazil and their relationship with success rates after assisted reproduction treatment: an integrative review. **2021**, 25, 136-149   0

149   Unconventional Ovarian Stimulation for Medically Assisted Reproduction. **2020**, 157-158

148   Follicular Flushing at Oocyte Retrieval in Medically Assisted Reproduction. **2020**, 763-765

147   Assisted Reproductive Technologies. **2020**, 1-22

146   Duration of ovarian stimulation is predictive of in-vitro fertilization outcomes. **2019**, 71, 419-426   1

145   The number of oocytes as a predictor of pregnancy rates in the cycles of assisted reproductive technology. **2020**, 7, 53-58

144   Optimal numbers of mature oocytes to produce at least one or multiple top-quality day-3 embryos in normal responders. **2020**, 47, 221-226   2

143   The past, present, and future of embryo selection in in vitro fertilization: Frontiers in Reproduction Conference. **2011**, 84, 487-90   18

142   Effect of lower than expected number of oocyte on the IVF results after oocyte-pickup. **2014**, 7, 1853-9   4

141   Ovarian Sensitivity Index (OSI): Validating the Use of a Marker for Ovarian Responsiveness in IVF. **2019**, 20, 83-88   2

140   No influence of the indication of freeze-all strategy on subsequent outcome to frozen-thawed embryo transfer cycle. **2018**, 10, 85-91   1

139   Outcomes of Preimplantation Genetic Testing for Single Gene Defects in a Privately Funded Period and Publicly Funded Period: A North-American Single Center Experience. **2020**, 21, 107-115

138   The Maximum Effective Dose of FSH for Ovarian Stimulation in IVF Is 300 IU. **2021**, 222-224

137   Does the freeze-all strategy improve the cumulative live birth rate and the time to become pregnant in IVF cycles?. **2021**,   0

136   Ovarian Hyperstimulation Syndrome. **2021**, 139-145

135   A study on the impact of elevated estradiol levels in frozen-embryo transfer cycles on pregnancy rates. *Fertility Science and Research*, **2021**, 8, 144   0.1

134   Informative predictors of pregnancy after first IVF cycle using eIVF practice highway electronic health records.. **2022**, 12, 839   0

133	Optimal individualization of patient-oriented ovarian stimulation in Japanese assisted reproductive technology clinics, a review for unique setting with advanced-age patients.. **2022**,		
132	Live birth, cumulative live birth and perinatal outcome following assisted reproductive treatments using donor sperm in single women vs. women in lesbian couples: a prospective controlled cohort study.. *Journal of Assisted Reproduction and Genetics*, **2022**, 1	3.4	0
131	Effect of Genetic Variants of Gonadotropins and Their Receptors on Ovarian Stimulation Outcomes: A Delphi Consensus.. *Frontiers in Endocrinology*, **2021**, 12, 797365	5.7	1
130	Fertility preservation in transgender men without discontinuation of testosterone. **2022**,		0
129	Assistierte Reproduktion. **2021**, 1-30		
128	Efficacy of using recombinant granulocyte colony-stimulating factor in IVF/ICSI protocols in patients with predicted suboptimal response to controlled ovarian stimulation. **2022**, 71, 59-70		
127	A Retrospective Study on the Use of High-Dose Letrozole while Undergoing Ovarian Stimulation for Oocyte and Embryo Cryopreservation in Cancer Patients. **2022**, 10, 19-26		
126	Machine Learning-Based Modeling of Ovarian Response and the Quantitative Evaluation of Comprehensive Impact Features.. **2022**, 12,		1
125	Impact of governmental support to the IVF clinical pregnancy rates: differences between public and private clinical settings in Kazakhstan-a prospective cohort study.. **2022**, 12, e049388		0
124	Identification of miR-34-3p as a Candidate Follicular Phase Serum Marker for Endometriosis: a pilot study. **2022**,		
123	Effectiveness of music therapy as an adjuvant to conscious sedation in women undergoing transvaginal oocyte retrieval: A randomized controlled trial.. **2022**,		
122	Ovarian Sensitivity Decreased Significantly in Patients With Insulin Resistance Undergoing Fertilization and Embryo Transfer.. **2021**, 12, 809419		2
121	Cumulative live birth rates for low-prognosis women over 5 years or 9 frozen-thawed embryo transfer cycles.. **2022**, 22, 233		0
120	Effect of cigarette smoking on serum anti-Mullerian hormone and antral follicle count in women seeking fertility treatment: a prospective cross-sectional study.. **2022**, 12, e049646		0
119	Ovarian reserve parameters and IVF outcomes in 510 women with poor ovarian response (POR) treated with intraovarian injection of autologous platelet rich plasma (PRP).. **2022**, 14,		3
118	Effect of rLH Supplementation during Controlled Ovarian Stimulation for IVF: Evidence from a Retrospective Analysis of 1470 Poor/Suboptimal/Normal Responders Receiving Either rFSH plus rLH or rFSH Alone.. **2022**, 11,		0
117	A nomogram to assist blastocyst selection in vitrified-warmed embryo transfer cycles.. **2022**,		1
116	Sleep, psychological distress, and clinical pregnancy outcome in women and their partners undergoing in vitro or intracytoplasmic sperm injection fertility treatment.. **2021**,		0

97	Table_2.docx. **2020**,
96	Table_3.docx. **2020**,
95	Table_4.docx. **2020**,
94	Table_5.docx. **2020**,
93	Table_6.docx. **2020**,
92	Table_7.docx. **2020**,
91	Table_8.xlsx. **2020**,
90	Video_1.MOV. **2020**,
89	Data_Sheet_1.docx. **2020**,
88	Data_Sheet_1.docx. **2020**,
87	Table_1.docx. **2018**,
86	Data_Sheet_1.docx. **2019**,
85	Table_1.DOCX. **2019**,
84	Table_2.DOCX. **2019**,
83	Table_3.DOCX. **2019**,
82	Data_Sheet_1.docx. **2020**,

| 81 | Live-Birth Prediction of Natural-Cycle Fertilization Using 57,558 Linked Cycle Records: A Machine Learning Perspective.. *Frontiers in Endocrinology*, **2022**, 13, 838087 | 5.7 | 1 |

| 80 | Stimulation Duration in Patients with Early Oocyte Maturation Triggering Criteria Does Not Impact IVF-ICSI Outcomes.. **2022**, 11, |

79	Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get?. **2022**,		0
78	Predicting in vitro fertilization success in the Brazilian public health system: a machine learning approach.. **2022**, 1		0
77	Algorithm-based individualization methodology of the starting gonadotropin dose in IVF/ICSI and the freeze-all strategy prevent OHSS equally in normal responders: a systematic review and network meta-analysis of the evidence.. *Journal of Assisted Reproduction and Genetics*, **2022**,	3.4	0
76	An interpretable machine learning model for predicting the optimal day of trigger during ovarian stimulation.. **2022**,		2
75	Regulatory Role and Potential Importance of GDF-8 in Ovarian Reproductive Activity. *Frontiers in Endocrinology*, **2022**, 13,	5.7	0
74	Comparison of the luteal phase estradiol priming stimulation and standard antagonist protocols in patients with diminished ovarian reserve undergoing ICSI. **2022**, 6, 577-581		
73	Endometriosis and Infertility: A Long-Life Approach to Preserve Reproductive Integrity. **2022**, 19, 6162		0
72	An Online Tool Using Basal or Activated Ovarian Reserve Markers to Predict the Number of Oocytes Retrieved Following Controlled Ovarian Stimulation: A Prospective Observational Cohort Study. *Frontiers in Endocrinology*, **2022**, 13,	5.7	0
71	Analysis of IVF/ICSI outcomes in infertile women with early-stage endometrial cancer and atypical endometrial hyperplasia after conservative treatment. *Journal of Assisted Reproduction and Genetics*,	3.4	
70	Oocyte recovery rates in flushing versus nonflushing during oocyte retrieval in assisted reproductive techniques. *Fertility Science and Research*, **2021**, 8, 36	0.1	
69	Current Applications of Machine Learning in Medicine: ART. **2022**, 121-147		
68	Supporting first FSH dosage for ovarian stimulation with Machine Learning. *Reproductive BioMedicine Online*, **2022**,	4	
67	Low Luteal Serum Progesterone Levels Are Associated With Lower Ongoing Pregnancy and Live Birth Rates in ART: Systematic Review and Meta-Analyses. *Frontiers in Endocrinology*, 13,	5.7	0
66	Aspiration of excess follicles before intrauterine insemination in high response cycles. *Reproductive Medicine and Biology*, **2022**, 21,	4.1	
65	Basal serum level of 4-androstenedione reflects the ovaries ability to respond to stimulation in IVF cycles: setting up a new reliable index of both ovarian reserve and response. *Journal of Assisted Reproduction and Genetics*,	3.4	
64	Gonadotropin Stimulation Reduces the Implantation and Live Birth Rate but Not the Miscarriage Rate of Embryos Transferred When Compared to Unstimulated In Vitro Fertilization. *Reproductive Sciences*,	3	
63	Pregnancy rate in IVF patients with unexpected poor response to ovarian stimulation. *Gynecological Endocrinology*, 1-6	2.4	
62	Faster Fertilization and Cleavage Kinetics Reflect Competence to Achieve a Live Birth: Data from Single-Embryo Transfer Cycles. *BioMed Research International*, **2022**, 2022, 1-9	3	0

61	Comparison between Single and Double Cleavage-Stage Embryo Transfers, Single and Double Blastocyst Transfers in a South East Asian In Vitro Fertilisation Centre. *Annals of the Academy of Medicine, Singapore*, **2018**, 47, 451-454	2.8	4
60	Future Fertility of Patients With No Embryo Transfer in Their First IVF Cycle Attempts. *Frontiers in Endocrinology*, 13,	5.7	
59	Comparison of two ovarian stimulation protocols among women with poor response: A randomized clinical trial.		
58	Clomiphene citrate priming increases sensitivity during ovarian stimulation in poor ovarian responders undergoing in´vitro fertilization treatment: a retrospective cohort study. 1-7		
57	Low Oocyte Maturity Rate and Asynchronous Follicle Development: Other Unnoticed Groups in the Bologna Criteria for Poor Responders?. **2022**, 23, 216-219		
56	The case for mild stimulation for IVF: ISMAAR recommendations. **2022**,		
55	Controlled Ovarian Stimulation. **2022**, 112-124		
54	Uterine factors modify the association between embryo transfer depth and clinical pregnancy. **2022**, 12,		
53	Artificial Oocyte Activation. **2022**, 143-152		
52	The effect of polymorphisms in FSHR gene on late follicular phase progesterone and estradiol serum levels in predicted normoresponders.		0
51	Relation´of graphical follicle models to´the cumulative live birth rate in GnRH-antagonist stimulation treatment cycles.		0
50	On the reproductive capabilities of aneuploid human preimplantation embryos. **2022**, 109, 1572-1581		1
49	Predicting IVF outcome in poor ovarian responders. **2022**, 22,		0
48	Association of follicle-to-oocyte index and clinical pregnancy in IVF treatment: A retrospective study of 4,323 fresh embryo transfer cycles. 13,		0
47	Retrospective analysis of GnRH-a prolonged protocol for in vitro fertilization in 18,272 cycles in China. **2022**, 15,		0
46	Fertility preservation for pediatric patients with hemoglobinopathies: Multidisciplinary counseling needed to optimize outcomes. 13,		0
45	Intracytoplasmic sperm injection cycle success in patients under 35 years old with diminished ovarian reserve plus severe male factor.		0
44	Assisted Reproductive Technology and Natural Law: How Seven Years as an Embryologist Revealed IVF's Disordered Approach to Patient Care. 002436392211283		0

43	The Effect of Stimulation Protocols (GnRH Agonist vs. Antagonist) on the Activity of mTOR and Hippo Pathways of Ovarian Granulosa Cells and Its Potential Correlation with the Outcomes of In Vitro Fertilization: A Hypothesis. **2022**, 11, 6131	0
42	Comparing pregnancy rates following ovarian stimulation with follitropin- to follitropin - in routine IVF: A retrospective analysis. **2023**, 280, 22-27	0
41	Prediction model of gonadotropin starting dose and its clinical application in controlled ovarian stimulation. **2022**, 22,	0
40	LH increases the response to FSH in granulosa-lutein cells from sub/poor-responder patients in vitro.	0
39	Short agonist stop protocol, an ovarian stimulation for poor responders in in vitro fertilization (IVF): A pilot study. 13,	0
38	Do the Number of Oocytes Retrieved and Mature Oocyte Rate in the Cohort Affect IVF Results?.	0
37	Should Preimplantation Genetic Testing (PGT) Systematically Be Proposed to BRCA Pathogenic Variant Carriers?. **2022**, 14, 5769	0
36	A randomized, non-inferiority trial on the DuoStim strategy in PGT-A cycles. **2022**,	0
35	Live birth is not the only relevant outcome in research assessing assisted reproductive technology. **2022**, 102306	0
34	FSH (and LH) in ovarian stimulation Does the dose matter for cycle success?. **2022**,	0
33	Association between number of oocytes and cumulative live birth rate: a systematic review. **2022**, 102307	1
32	Treatment algorithms for high responders: what we can learn from randomized controlled trials, real-world data and models. **2022**, 102301	0
31	What should be the strategy in case of a big follicle at the start of the cycle? Shall we start the stimulation or postpone it to the next cycle?. **2022**, 19, 275-280	0
30	Impact of the number of retrieved oocytes on IVF outcomes: oocyte maturation, fertilization, embryo quality and implantation rate. 1-6	1
29	More follicle-stimulating hormone may not improve outcomes, but can it be counterproductive?. **2022**,	0
28	Evaluation of correlation between antral follicle diameters with Follicular Output Rate (FORT) in women under controlled ovarian hyperstimulation for assisted reproductive techniques. **2022**, 11,	0
27	The average gonadotrophin dosage per follicle is predictive of ovarian response and cumulative live birth chances after in vitro fertilization: a retrospective cohort study.	0
26	Correlation of IVF outcomes and number of oocytes retrieved: a UK retrospective longitudinal observational study of 172 341 non-donor cycles. **2023**, 13, e064711	1

25	FSH administration at 12-hour intervals for the first 2 days, combined with mandatory GnRH-agonist trigger and blastocyst vitrification in women (<80Kg) with high AMH levels, results in higher cumulative live birth rates and is safer. 1-8	0
24	A higher number of oocytes retrieved is associated with an increase in 2PNs, blastocysts, and cumulative live birth rates. **2023**,	1
23	Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS). **2022**, 102308	0
22	Freeze-all embryos during treatment with assisted reproduction: Health economic aspects. **2022**, 102303	0
21	How to choose the appropriate ART technique and counseling about reproductive outcomes. **2023**, 165-171	0
20	Impact of Insulin Resistance on Ovarian Sensitivity and Pregnancy Outcomes in Patients with Polycystic Ovary Syndrome Undergoing IVF. **2023**, 12, 818	0
19	The gonadotropins starting dose calculator, which can be adjusted the target number of oocytes and stimulation duration days to achieve individualized controlled ovarian stimulation in Japanese patients. **2023**, 22,	0
18	An online tool for predicting ovarian responses in unselected patients using dynamic inhibin B and basal antimüllerian hormone levels. 14,	1
17	Why ovarian stimulation should be aimed to maximize oocyte yield. **2023**,	0
16	High-Risk genotypes associated with poor response to controlled ovarian stimulation in Indian women. **2023**, 16, 70	0
15	IDoser: Improving individualized dosing policies with clinical practice and machine learning.	0
14	The average gonadotrophin dosage per follicle is predictive of ovarian response and cumulative live birth chances after in vitro fertilization: a retrospective cohort study. **2023**, 23,	0
13	Blastocyst Transplantation Strategies in Women of Different Ages. **2023**, 12, 1618	0
12	Impact of Antithyroperoxidase Antibodies (Anti-TPO) on Ovarian Reserve and Early Embryo Development in Assisted Reproductive Technology Cycles. **2023**, 24, 4705	0
11	The live birth rate of vitrified oocyte accumulation for managing diminished ovarian reserve: a retrospective cohort study. **2023**, 16,	0
10	The combined effect of BMI and age on ART outcomes.	0
9	Adherence to the Mediterranean diet and the risk of unexpected poor response to ovarian stimulation in IVF cycles. **2023**,	0
8	The HERA (Hyper-response Risk Assessment) Delphi consensus definition of hyper-responders for in-vitro fertilization.	0

7	The effect of the embryo pooling method on the cumulative live birth rate in poor ovarian responders according to the Bologna criteria.	o
6	The influence of reproductively significant autoantibodies determined in the follicular fluid on the quality of the obtained oocytes and embryos, as well as on the implantation rate in assisted reproductive technology cycles. **2023**, 72, 39-52	o
5	Cumulative live birth rates and birth outcomes after IVF/ICSI treatment cycles in young POSEIDON patients: A real-world study. 14,	o
4	Ovarian Stimulation with FSH Alone versus FSH plus a GnRH Antagonist for Elective Freezing in an Oocyte Donor/Recipient Programme: A Protocol for a Pilot Multicenter Observational Study. **2023**, 12, 2743	o
3	Effectiveness and Safety of Recombinant Human Follicle-Stimulating Hormone (Follitrope) in Inducing Controlled Ovarian Stimulation in Infertile Women in Real-World Practice: a Prospective Cohort Study.	o
2	A Monocentric Randomized Controlled Clinical Trial to Compare Single- and Double-Lumen Needles in Oocyte Retrieval Procedure in Assisted Reproductive Technologies.	o
1	Number of oocytes and IVF outcomes: Real World Evidence. **2023**, 102341	o